"Dec. 3, 2012 -- One of the oldest, cheapest, and most widely used diabetes drugs may be a promising new cancer treatment.
In new research from the Mayo Clinic, ovarian cancer patients who took the drug metformin survived longer than p"...
- Patient Information:
Details with Side Effects
See BOXED WARNINGS.
Concurrent administration of HEXALEN® (altretamine) capsules and antidepressants of the monoamine oxidase (MAO) inhibitor class may cause severe orthostatic hypotension. Four patients, all over 60 years of age, were reported to have experienced symptomatic hypotension after 4 to 7 days of concomitant therapy with HEXALEN® (altretamine) capsules and MAO inhibitors.
HEXALEN® (altretamine) capsules causes mild to moderate myelosuppression and neurotoxicity. Blood counts and a neurologic examination should be performed prior to the initiation of each course of therapy and the dose of HEXALEN® (altretamine) capsules adjusted as clinically indicated (see DOSAGE AND ADMINISTRATION).
Pregnancy: Category D
HEXALEN® (altretamine) capsules has been shown to be embryotoxic and teratogenic in rats and rabbits when given at doses 2 and 10 times the human dose. HEXALEN® (altretamine) capsules may cause fetal damage when administered to a pregnant woman. If HEXALEN® (altretamine) capsules is used during pregnancy, or if the patient becomes pregnant while taking the drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.
Neurologic examination should be performed regularly (see ADVERSE REACTIONS).
Peripheral blood counts should be monitored at least monthly, prior to the initiation of each course of HEXALEN® (altretamine) capsules, and as clinically indicated (see ADVERSE REACTIONS).
Carcinogenesis, Mutagenesis and Impairment of Fertility
The carcinogenic potential of HEXALEN® (altretamine) capsules has not been studied in animals, but drugs with similar mechanisms of action have been shown to be carcinogenic. HEXALEN® (altretamine) capsules was weakly mutagenic when tested in strain TA100 of Salmonella typhimurium. HEXALEN® (altretamine) capsules administered to female rats 14 days prior to breeding through the gestation period had no adverse effect on fertility, but decreased post-natal survival at 120 mg/m²/day and was embryocidal at 240 mg/m²/day. Administration of 120 mg/m²/day HEXALEN® (altretamine) capsules to male rats for 60 days prior to mating resulted in testicular atrophy, reduced fertility and a possible dominant lethal mutagenic effect. Male rats treated with HEXALEN® (altretamine) capsules at 450 mg/m²/day for 10 days had decreased spermatogenesis, atrophy of testes, seminal vesicles and ventral prostate.
Pregnancy Category D: see WARNINGS section.
It is not known whether altretamine is excreted in human milk. Because there is a possibility of toxicity in nursing infants secondary to HEXALEN® (altretamine) capsules treatment of the mother, it is recommended that breast feeding be discontinued if the mother is treated with HEXALEN® (altretamine) capsules.
The safety and effectiveness of HEXALEN® (altretamine) capsules in children have not been established.
1.Wiernik PH, et al. Hexamethylmelamine and Low or Moderate Dose Cisplatin With or Without Pyridoxine for Treatment of Advanced Ovarian Carcinoma: A Study of the Eastern Cooperative Oncology Group. Cancer Invest. 1992; 10(1): 1-9.
Last reviewed on RxList: 10/9/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Hexalen Information
Hexalen - User Reviews
Hexalen User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.